Categories Earnings Call Transcripts, Health Care

Amarin Corporation plc  (NASDAQ: AMRN) Q1 2020 Earnings Call Transcript

AMRN Earnings Call - Final Transcript

Amarin Corporation plc  (AMRN) Q1 2020 earnings call dated Apr. 13, 2020

Corporate Participants:

Elisabeth Schwartz — Senior Director of Investor Relations

John Thero — President and Chief Executive Officer

Presentation:

Operator

Greetings, welcome to Amarin Corporation’s Conference Call to discuss its preliminary first quarter financial results and operational updates. This conference call is being recorded today, April 13th, 2020. I would like to turn the conference over to Elisabeth Schwartz, Senior Director of Investor Relations of Amarin. Thank you, you may begin.

Elisabeth Schwartz — Senior Director of Investor Relations

Please be aware that this conference call will contain forward-looking statements that are intended to be covered under the Safe Harbor provided by the Private Securities Litigation Reform Act. Examples of such statements include, but are not limited to, our current expectations regarding our commercial and financial performance, including levels of the VASCEPA prescriptions, VASCEPA product and licensing revenues, costs and other commercial metrics, gross margin, expenditures such as for the purchase of additional supply of VASCEPA, and the adequacy of our financial resources; our current plans and expectations for product revenue growth and product promotion in light of COVID-19 and any potential for added cardiovascular risk attention to VASCEPA as a result of COVID-19; our current plans and expectations regarding appealing the District Court VASCEPA related patent litigation decision to the Federal Court; and our current plans and expectations for a potential launch of a generic version of VASCEPA by generic companies and by ourselves, including expectations regarding and approvals by the FDA, generic cost effective supply availability, timing, potential levels of damages and ability to recover VASCEPA growth if the appeal succeeds. Our current expectations for regulatory reviews outside the United States regarding VASCEPA approval and regulatory reviews inside the United States regarding consumer promotion and related timing thereof; our expectations regarding sales force productivity, our goals regarding the timing, scope, and success of international expansion including expectations regarding our ability to launch VASCEPA in Europe directly or through a potential partner, our current plans for a commercial expansion in the United States, our current plans for spending, and our expectations regarding the use and adequacy of our resources.

These statements are based on information available to us today, April 13th, 2020. We may not actually achieve our goals, carry out our plans or intentions or meet the expectations disclosed in our forward-looking statement. Actual results or events could differ materially. So you should not place undue reliance on these statements. We assume no obligation to update these statements as circumstances change. Our forward-looking statements do not reflect the potential impact of significant transactions we may enter into such as mergers, acquisitions, dispositions, joint ventures or any material agreements that we may enter into, amend or terminate. For additional information concerning the factors that could cause actual results to differ materially, please see the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31st, 2019 as well as our Forms 8-K filed subsequent to our Form 10-K. These documents have been filed with the SEC or are available through the Investor Relations section of our website at amarincorp.com. We encourage everyone to read these documents. This call is intended for investors in Amarin and is not intended to promote use of VASCEPA outside its approved indication. An archive of this call will be posted on the Amarin website, also in the Investor Relations section. I will now turn the call over to John Thero, President and Chief Executive Officer of Amarin.

John Thero — President and Chief Executive Officer

Hello everybody, thank you for joining us today. During this call, we intend to cover a variety of topics including an update on the launch of VASCEPA in the United States for it’s relatively new cardiovascular risk reduction indication, our ANDA situations and plans to vigorously pursue reversal of the District Court decision and continued VASCEPA sales growth, the impact of COVID-19 on our operations and exploration being considered for potential use of VASCEPA to help COVID-19 patients at high cardiovascular risk. Lastly, we’ll include some updates on the large international opportunities for VASCEPA.

First, I want to express my gratitude to our many investors who despite losing money after the District Court’s [Indecipherable] negative decision on our ANDA litigation reached out to Amarin expressing messages of support and offering constructive suggestions. While we cannot respond directly to all such messages, please know that each are reviewed thoughtfully and how we appreciate all constructive advice. One purpose of this call is to share with you key elements of our current thinking regarding Amarin’s strategy and future. As I’m sure you appreciate, we don’t have all of the answers to the continually changing landscape brought on by COVID-19 and the ANDA litigation decision. In addition, there are of course, tactical reasons that prevent us from detailing on this publicly available call, our plan to appeal arguments and related commercial strategies rather than having them conveyed through court proceedings and in the field. I intend to cover significant details on this call. I expect that my comments will consume more than 30 minutes.

To set the tone for this call, Amarin has confidence that we will create significant shareholder value. At this point, our intention is to drive updates on matters which we understand to be the most important to investors. As noted in our call announcement, we have not scheduled a Q&A period at the end of this conference call. In the ordinary course, in conjunction with our Q1 results call, we will provide additional financial and operational updates and we plan to take questions at that time. I start by giving a preview of Q1 2020 results. We ended March 2020 with more than $620 million in cash and short-term investments and less than $50 million remaining due on our royalty like debt instrument such that we are well capitalized to get to cash flow positivity based upon our current resources. The launch of VASCEPA in 2020 got off to a good start in Q1 as the first and only drug for reducing persistent cardiovascular risk beyond statin therapy as per the new indication approved by the FDA near the end of 2019. We hired a terrific sales team and expanded our managed care field team. We trained a well-respected group of physicians to help support medical education. We advanced our proposed consumer promotion with the FDA for our previously intended DTC program launch in the coming months and we witnessed prescription levels grow in the first quarter to levels which exceeded our Q1 expectations.

Regarding Q1 2020 net total revenue, our preliminary estimate is that it totaled approximately $150 million with potential to be modestly higher when finalized with the amounts for international revenue including revenue from Canada where VASCEPA was launched in Q1, licensing revenue and other considerations. This $150 million estimate predominantly reflects VASCEPA sales in the United States. At $150 million, net total revenue in the first quarter of 2020 would be approximately 105% more than the $73.3 million in net total revenue that we reported in the first quarter of 2019. This revenue growth was driven by increased prescription levels for VASCEPA. Based upon the preliminary information available to us at this time, it appears that we witnessed increased prescription levels both from doctors who previously prescribed VASCEPA as well as from new writers and some of our greatest areas of growth included areas of the United States where we did not have sales representatives a year ago. As you know, we recently increased the size of our U.S. sales team to 800 sales representatives plus their managers from the 400 we had in place for most of 2019. As mentioned earlier, if the sales representatives we hired as part of our recent expansion become as rapidly productive as did the sales representatives we hired last year, the 2020 revenue guidance range that we provided at the start of 2020 which was a target range of $650 million to $700 million was likely conservative.

Based on review of Q1 results during which revenue growth was coming on particularly strong in the month of March, we were considering increasing our revenue guidance for the year. This, of course, was before the model adjustments we have been forced to consider resulting from the hopefully temporary market impact of COVID-19 and the uncertainties related to the court ruling in our patent litigation. I’ll revisit the topic of financial guidance in a moment. Before going there, I need to acknowledge that many unknowns exist due to the challenges and potential opportunities created by COVID-19 and due to the patent litigation ruling and our planned appeal. The Amarin team has overcome numerous challenges in the past. Our people are highly motivated to help improve patient care. If we are not successful, too many patients will likely never benefit from VASCEPA because both product related education and further product related research and development won’t be funded or championed. We have come too far to stop fighting now. We took on product development in the MARINE, ANCHOR and REDUCE-IT studies and against the expectations of the masses, we showed unprecedented results. We won past legal battles on numerous topics including new chemical entity status and the First Amendment communication rights. We have smart and dedicated people who are working as a team. We don’t like being told that we can’t overcome an obstacle when the obstacle puts patients at risk. Moreover, we are all shareholders of Amarin and we intend to continue to fight vigorously for what we believe is right and best. In the aftermath of both the COVID-19 and the ANDA court ruling, I am proud to witness the team at Amarin aggressively seeking out solutions and finding ways to advance our important priorities.

Also Read:  FactSet Research Systems Inc. (FDS) Q4 2020 Earnings Call Transcript

Regarding the district court ruling in the ANDA Litigation, as previously communicated, we were surprised and disappointed that the court determined that patent upon which we relied to build our business should be considered invalid based upon arguments of perceived obviousness. In doing so, in my view, the court decision not only did not fully appreciate the importance of VASCEPA as a unique and valuable breakthrough therapy for which I believe there is considerable evidence, but it also overturned the decision of the U.S. Patent Office, which earlier had granted our patents after a thorough review of prior arch [Phonetic] and after its own consideration of obviousness. We understand that it is difficult to look back at VASCEPA product development, the genesis of which commenced over a decade ago and past judgment on what was understood by people at the time. However, I was part Amarin at that time, but I can assure you that investors and experts did not think that what Amarin was pursuing was obvious. For example, I recall at that time that Glaxo was looking for a next-generation product for Lovaza. Based upon my recollection of communications with them at the time, they didn’t expect to find that solution in peer EPA. Rather, they were like other big pharma companies that had dismissed omega-3 as a solution. Big pharma companies at that time to the extent that they were focusing in on cardiovascular disease were focusing in on statins, CETP inhibitors, making niacin better tolerated and on fenofibrate, not on treating severely high triglyceride levels. Furthermore, as a reminder, the world was in a recession in that time frame. Few new product development initiatives were being funded and when they were funded, it was based upon well vetted scientific insight. Amarin completed one of the largest healthcare financings in that time frame because of its scientific insights. We have shown repeatedly over the past decade that the scientific aspects behind omega-3s, lipid management and cardiovascular care are each complex. Perhaps the elegance of our solution today makes it look easy in hindsight, but that was not the case at the time. We understand that the science is complex and that the presentation of such materials in a court setting can be challenging. It is not my intention in these comments to show disrespect to the judge. A decade ago, had the science been understood by others the way that it was understood by Amarin, GSK likely would have found a replacement for Lovaza in an EPA only drug and or Epadel, the product used in Jelis [Phonetic] would have been developed in other populations and perhaps found use globally and or AstraZeneca, the NIH, and the British Heart Foundation would not have funded large outcome studies of omega-3 mixtures.

In fact [Phonetic], just last month, a lead investigator who participated in AstraZeneca’s STRENGTH trial had data from his lab presented showing unique effects of EPA compared to other omega-3s. Such insights are important. However, regarding timing, those observations in 2020 came nearly a decade after we filed patents that speak to the uniqueness of VASCEPA and it’s active ingredient icosapent ethyl based upon pure and stable EPA. When we started the MARINE trial, people were worried that we were allowing statin treated patients into the study because they had not been studied with earlier generation triglyceride lowering drugs and they worried that the triglyceride lowering effects of Vascepa would be mitigated by the triglyceride lowering effects of statin therapy. Nonetheless, we were insistent on treating patients who were treated to the then current standards of care. The MARINE study was, as you know, very successful. When the results of the MARINE study became known, I recall the investigators marveling at the triglyceride lowering effects without an increase in LDL cholesterol and how different this was than other therapies. These were reactions by leading physicians. For the Amarin scientific team, the results were gratifying as they saw their insight demonstrated in a statistically significant trial, the design of which had been completed under a Special Protocol Assessment agreement with the FDA. Recall that successful MARINE study results were needed by the FDA as support for the indication sought in the ANCHOR trial and for getting to the REDUCE-IT study all of which was outlined with the FDA more than a decade ago. I recognize that it is difficult for people to go back in time to do such analysis. For these and other reasons, I do not believe that the U.S. Patent Office should have been overruled in assessing that the patents for VASCEPA were not obvious. Hindsight is unfortunately a power force in the human mind. Much that is not obvious at a point in time can then appear obvious after it is discovered. The appeal process likely won’t focus on much of the content which I just expressed and therefore such arguments matter little except as to provide you with some context in support for our broader belief that our patents should have been upheld as inventive and not obvious.

Rather than re-hearing the case, the appeal will focus on arguments of a more legal nature and important factual errors. The aim of an appeal is to persuade through a legal argument a panel of three specialized Federal Court judges that the ANDA decision should be overturned or reconsidered when the law is applied properly and factual errors are corrected. Accordingly, please do not expect that appeals are openings to re-try the case. Please do not expect that every element that you may think is wrong in the judge’s decision will be appealed. That is not the nature of an appeal in this setting. For success, we need to effectively persuade the federal judges that the District Court opinion is wrong based upon errors of law and fact that bear on its opinion. We believe that we have numerous arguments that will contribute to a strong substantive appeal. Many of you have expressed to us examples of arguments that go to point that could be argued on appeal. At this time, we are not going to communicate which arguments will be emphasized. When our appeal is submitted, likely in early May, such arguments will be public. We believe our outside counsel in the District Court matter made a convincing case.

All experienced independent commentators took a serious look at the record agree the trial should have resulted in a judgment for Amarin. Looking forward, we have determined that the importance of this case on appeal calls for the addition to the team of a fresh perspective on the record. The nature of arguing an appeal in this field is specialized and we have accordingly added to our legal team a new lead counsel for this matter who like our trial counsel is a recognized leader in the field and has won cases of this nature at the Federal Circuit. Our new lead counsel will work with our in-house team and the team that argued the matter in the District Court. We believe our team going forward is well situated to make the most of the case and we believe we’re favorably positioned to put forward a strong case on appeal. Our aim is to expedite the appeal proceedings towards a hearing and judgment as soon as possible. We are aiming for the matter to be heard in oral argument in the summer after briefings are completed with a judgment as soon as possible thereafter. We can and are working to expedite, but we do not control the court schedule. However, we hope to have more details on timing of the briefing schedule over the next week or two. When substantive briefs are filed with the Federal Circuit for this appeal, they will become publicly available through PACER, the Internet-based docket publication platform.

Based on actions of the generic companies after the court testimony in Nevada, I doubt that they thought that they won the litigation. The uniqueness and inventive nature of VASCEPA has been well recognized for years as was well documented in the U.S. Patent Office. There was the unanimous view of those lawyers and analysts reporting on the matter that Amarin had made a winning case at trial. The uniqueness of VASCEPA was further evidenced by the success of the REDUCE-IT study and by the early stopping of the competitive study STRENGTH [Phonetic] due to its low likelihood of demonstrating benefits and to numerous accolades for VASCEPA from medical societies and key opinion leaders. In most such situations where generic companies win at the district level and there is a reasonable basis for a reversal on appeal, they wait for completion of the appeal before launching a generic product. While we believe that may be the likely result here, we cannot be sure that one or more of the generic companies won’t be daring and launch if they get FDA approval and can launch during the appeal process. If such generic companies get their ANDAs approved by the FDA, have qualified supply, and elect to launch during the appeal process, they do so at risk that we will win the appeal. Given both the nature of the appeal and the arguments we intend to make and reflecting on the potential size of the damages which could be imposed on them if we prevail in the appeal, their launching at risk would be surprising. Nonetheless, we intend to be prepared for such an unlikely circumstance. Damage awards, if they elect to launch and we prevail on the appeal, could be very significant. If we are in a position of seeking damages from generics, we, of course, will seek all we can including at very least, the full amount of lost profits available to us. Our intention is to fight vigorously on the appeal and assuming we win, to fight vigorously for compensation for damages if the generic launch occurs by one or more generic companies.

Also Read:  Usa Technologies Inc. (USAT) Q4 2020 Earnings Call Transcript

The generic companies also know by now that Amarin has spent large amounts of resources over years to develop cost effective supply capacity for global sales and that as VASCEPA is our only product, we will seek to maximize this global opportunity for Amarin. They should also know that Amarin could launch its own authorized generic product. The trade-off for launching a generic product whether that generic product is launched in parallel or with a branded product or in place of a branded product is that the generic product model does not provide for product related education and promotion. Typically, generic products are launched near the end of a product lifecycle. It has been argued by some that it is good for a generic product to be launched in an established market where the need for education is low if the generic product is inexpensive [Phonetic]. However, the price of VASCEPA has been assessed to be cost effective by many of the harshest critics of drug pricing. Given the relatively high cost of producing VASCEPA and the relatively low current price of VASCEPA, it is unlikely that the price of a generic version of VASCEPA will be much lower if lower at all than the net price of VASCEPA currently. Moreover, if a generic VASCEPA is launched soon, it will be launched at what is effectively the start of VASCEPA’s lifecycle for cardiovascular risk reduction in the United States. Such a launch would stifle the opportunity for VASCEPA to benefit the patient population, which has been the target of VASCEPA development for more than a decade. I recognize that there is a general societal perspective that generic drugs are good, but I am confident that many people on this call may recognize that many generic drugs are expensive and that there are many examples of an introduction of generic drugs, which results in less market education, less product development, and often less use of the drug. We have heard from various physicians who learned of the District Court decision. They expressed to us that they are worried that the market won’t be properly educated regarding VASCEPA. They recognize that while they know about VASCEPA, most healthcare professionals still have little knowledge of VASCEPA and that consumers have even less knowledge. Many of them have been urging us to increase educational efforts as we were planning to do assuming that as expected, the FDA approves our consumer promotion plans, which are currently under review with expected approval before the end of June.

While the courts may elect to not consider the likely negative impacts of a generic version of VASCEPA on society, if generic versions of VASCEPA are launched in the coming months or years, the potential of VASCEPA to benefit as many patients as possible will be undermined. Market education generally ceases when generic products are launched. For VASCEPA, this could lead to unnecessary heart attacks, strokes, and other high-cost cardiovascular events for lack of education about the drug’s benefits. In addition, if this court decision is not reversed following appeal, the undermining of VASCEPA’s path to success will likely further erode the rate of development of products for chronic ailments like cardiovascular disease as so many developers will observe that Amarin overcame great obstacles to develop VASCEPA only to have the opportunity thrown away before any profit was realized and before many patients might benefit. In our case, the launch of VASCEPA has just begun to physicians with much further education plan and a consumer education program, which is still undergoing FDA review for what was intended to be a launch later this year. Just last month, data presented at the 2020 Annual Scientific Session of the American College of Cardiology by Nathan Wong et all showed that VASCEPA assuming that the market is educated and VASCEPA becomes broadly used could potentially prevent more than 70,000 cardiovascular events per year. Before Hikma or Dr. Reddy’s can launch a generic version of VASCEPA, they need to get their ANDAs approved by the FDA. At this stage, Teva cannot launch a generic version of VASCEPA unless ANDA approval by the FDA and a generic version of VASCEPA is launched and we don’t obtain an injunction within 60 days. It would otherwise need to wait until August 2029 and unless we lose our case in the Federal Circuit. The timing of ANDA approval of generic versions of VASCEPA is unknown. Adding uncertainty is the impact of COVID-19 on FDA inspections of manufacturing facilities. We do not know if such facilities for Hikma or Dr. Reddy’s were previously inspected or not by the FDA as the FDA has curtailed site visits due to COVID-19. Their ANDAs were filed in 2016, but they are not yet FDA approved. Most likely, the FDA either didn’t take up the review of the ANDAs because the product couldn’t be launched due to regulatory exclusivity or the FDA took up the review and found issues.

The manufacture of VASCEPA is not easy. Amarin in concert with its manufacturing partners has been successful and consistently producing VASCEPA for commercial use since 2012. While our suppliers are reliable today, each API supplier we added during this growth period had to overcome setbacks often with Amarin’s help and investment as they advanced from pilot scale to commercial scale and as they work with us to pioneer efficiencies and cost savings in their facilities dedicated to production of VASCEPA API. The challenges of VASCEPA manufacturing do not stop with its purity. Such challenges extend to its stability including important steps in its isolation, encapsulation, and packaging. If the active ingredient is allowed to oxidize, it’s clinical effects may be impaired. For VASCEPA, because of the importance of product stability, we successfully tested the product for four years in capsule form. Achieving this result required extensive effort and focus. In qualifying new suppliers, improving long-term stability has been critical. Based upon the various publications of data regarding the fragile nature of EPA, any potential manufacturer of API for generic companies will have to consider how to best address these challenges recognizing that compromising could result in patients not getting the drug benefit they deserve.

Moreover, creating manufacturing supply is time consuming and expensive. If the generic companies don’t already have established capacity for VASCEPA at commercial scale and we are not aware that they have such proven commercial scale capacity, they will need to establish such a capacity just as Amarin established its capacity. In order to do this at substantial scale, for example, to be able to support $100 million or more in revenue, this growth and qualification is likely to be expensive and can take years to accomplish. In Amarin’s experience, many potential suppliers tried but failed in advancing from pilot scale to commercial scale within the high quality requirements of VASCEPA. In order to achieve high quality, potential shortcuts should be avoided. For example, it is not consistent with good manufacturing practices to ship Epadel API to VASCEPA API as the products are not identical and the drug master files are different. I mentioned this is an example of a potential shortcut although we are not aware of a glut of extra Epadel capacity. Perhaps a small amount can be identified but can’t be brought to the U.S. as a generic without FDA review. In any event, our view is that this would not be at a volume approaching the capacity needed to support retailer contracts for a generic version of a broadly used product like VASCEPA where this year we are purchasing more than a 1,000 metric tons of API. We have heard from various suppliers that they have been approached regarding supplying API for generic use. These suppliers informed us that they turned down such approaches for various reasons including that they don’t have excess capacity. We don’t have perfect visibility of the dynamics that could contribute to the timing and capacity of a generic launch, but we either have plans in place already or we are rapidly putting plans in place for a range of possible scenarios. We believe that there is an opportunity for shareholders to benefit under the most likely of these scenarios.

Let me now turn the discussion to coronavirus. COVID-19 has created both challenges and potential opportunities for expanded use of VASCEPA. As expressed earlier, our Q1 growth with VASCEPA exceeded our expectations and appeared to be on a strong trajectory for further growth. Following the environment of social distancing created by COVID-19, the outreach of our sales team to healthcare professionals has been more challenging and moreover, routine visits from patients to physicians have been curtailed. And some of the geographies, which are the most impacted by COVID-19 such as areas of New York and California are areas where VASCEPA was first launched and historically strongest for VASCEPA use. Our sales team is finding creative and professional ways to maintain contact with many healthcare professionals and on a year-over-year basis, we are continuing to see significant increases in VASCEPA shipments and TRx levels over the same period from a year ago. However, as is true for other drugs, new patient starts appear to have slowed in recent weeks. We are continuing to find new ways to reach out to healthcare professionals that which seemed odd a few weeks ago is becoming the norm today and we have plans ready for resuming direct sales calls when the company is ready for such safe in-person interactions likely rolled out on a regional basis.

Also Read:  Copart, Inc. (CPRT) Q4 2020 Earnings Call Transcript

In spite of COVID-19, we have continued to interact with Managed Care organizations and PBMs. We’re happy to report that insurance coverage for VASCEPA improved further at the start of April. You may recall in an earlier investor call that we spoke of multiple Blue Cross Blue Shield plans improving coverage for VASCEPA in three states during Q1. Subsequently, effective April 1, coverage for VASCEPA was moved to preferred brand status under Blue’s plans in 14 additional states. These are states were Blue’s plans are managed by Anthem. Previously, this class of drug, including Lovaza in both branded and generic form was not covered by Anthem plans as Anthem is historically a high control plan. The Anthem Blue’s plans tend to be the largest or second largest insurers in the states where they compete. Our sales team is excited about introducing this expanded coverage to physicians in these 14 states. Such pull through via physicians won’t be immediate, but it will help. In addition, while not as large in number of patients covered as the coverage improvements via Anthem, there have been two national plans under the CVS family of Managed Care plans where VASCEPA was not covered. As of April 1st, those two plans now cover VASCEPA as a preferred brand. With these changes, VASCEPA now has preferred brand coverage in 100% of the lives under CVS National Commercial Formularies. As a reminder, a preferred brand means not only is the product on formulary, but it also has the lowest co-pay for branded products.

The medical need for VASCEPA remains high. In the current environment, we expect to have continued year-over-year sales growth despite the impact of COVID-19. It is far too early to accurately quantify the impact of COVID-19 on revenue levels. We will revisit our revenue guidance for 2020 after we are able to resume direct in person sales calls with physicians. People with cardiovascular risk factors appear to be at greater risk for COVID-19. We, together with leading physicians on multiple continents of the world, are reviewing whether there are opportunities for VASCEPA to be used in acute or chronic settings to potentially mitigate heightened cardiovascular risks associated with COVID-19. Whether or not such efforts will succeed are not yet known nor do we yet know the extent of such potential investigation. However, we feel it is incumbent to try to help. Currently, such work is being evaluated based upon what is already known about VASCEPA, which is that it lowers cardiovascular risk in high-risk patients. If new data or other information presents itself regarding potential benefits of using VASCEPA in COVID-19 patients, we and/or our medical collaborators will make this known.

I promised that we’d also talk about international opportunities for VASCEPA. Cardiovascular disease remains the number one cause of death in the industrialized world regardless of how large a brand VASCEPA becomes in the U.S. the ANDA court decision in the U.S. should not impact the multi-billion dollar potential opportunities for VASCEPA outside the United States. As a reminder, via our partner in China, we have a clinical trial for VASCEPA which should report results later this year. We are informed that the impact of COVID-19 should not have a significant impact on the clinical results in China or on the timing of such results. Assuming clinical trial success, this will position VASCEPA to be first-in-class in China. For Europe, we continued to pursue a parallel process of evaluating whether to launch VASCEPA on our own in select countries and partnering in other countries or to enter into a pan-European partnership for the launch of VASCEPA. As previously reported, in Q4 2019, our regulatory submission for VASCEPA in Europe was accepted for review by the EMA. We seek a cardiovascular risk reduction indication in Europe. We intentionally did not go for the less valuable triglyceride lowering indication in Europe because we believe that reimbursement will be stronger based upon a cardiovascular risk reduction indication. In fact, based on the unprecedented results of REDUCE-IT, we believe that the net price of VASCEPA in Europe should be at least as high as the net price of VASCEPA in the United States because VASCEPA was launched in the United States as a triglyceride lowering agent in a market with generic products and without cardiovascular outcomes data. Our expectation is that VASCEPA will be approved near the end of this year for launch in Europe.

Regarding partnering, for reasons previously discussed, we waited to advance the partnering evaluation process for Europe until after we had a preliminary feedback from EMA regarding its questions pertaining to our regulatory submission. We have received such regulatory review feedback, the questions from which are somewhat analogous to the questions we received from Health Canada during their review. Pursuant to this added confidence and leverage, we are in the early stages of reviewing potential partners for Europe. Europe presents a large market opportunity for VASCEPA. We have been informed via the regulatory process that VASCEPA should qualify for 10 to 11 years of regulatory exclusivity in Europe and we expect our REDUCE-IT results to drive patent to extend the branded life of VASCEPA in Europe until mid-2033. While we have received considerable input from investors regarding whether it is best to go direct in Europe or best to partner in Europe, we believe it is best to see what proposals the partnering process produces and then to make a decision, most likely in the third quarter of this year. As a reminder of the large unmet medical need in Europe, there are more than 80 million people in Europe living with cardiovascular disease. This number is growing with approximately 11 million new cases of cardiovascular disease added each year in EU countries. Cardiovascular disease results in approximately 1.8 million deaths each year in Europe on top of a large number of debilitating events such as strokes and heart attacks resulting from cardiovascular disease. Caring for cardiovascular disease in Europe is expensive with annual spending estimated to currently exceed EUR200 billion annually. These data combined with clinical results from VASCEPA likely contributed to the medical guidelines issued by the European Society of Cardiology and the European [Indecipherable] Society recommending use of icosapent ethyl. Numerous key opinion leaders in Europe remain active in urging for the approval of VASCEPA in Europe to help improve care for their patients.

With regard to spending levels, while we are well capitalized, we seek to be judicious. We operated most of last year at a cash flow neutral to modestly cash flow positive level before increasing our promotional spending in conjunction with VASCEPA approval by the FDA at the end of 2019. We had intended for 2020 to be a year of substantial investment in market development for long-term benefit. In light of the U.S. patent litigation, we are reducing our planned spending levels in 2020. We are in the process of evaluating all of our spending commitments and priorities. Our spending priorities emphasize activities, which advance VASCEPA U.S. growth in the near-term, which advanced VASCEPA internationally and, which increased our likelihood of success upon appeal in the U.S. patent litigation matter. As part of this, we want to be prepared to accelerate our U.S. launch further if and when we win on the appeal. In pursuing these three areas of emphasis, it is our intention to pull back on certain areas of spending which are longer-term focused. For example, we had intended to invest significantly in patient and consumer education and promotion. However, such investment is expensive and tends to have a delayed benefit making it difficult to justify unless and until we win our patent related appeal. We intend to continue forward with our direct sales efforts as historically such efforts have rapidly paid for themselves. We will have more to say regarding our financial outlook after we get more clarity on the impact of COVID-19 on revenues and on whether not generic product is launched prior to conclusion of the appeal process. Overall, Amarin is confident that we will find pathways to create value for its shareholders from our operations in the United States and internationally. We have overcome greater challenges in the past. Amarin is well capitalized. Our revenues grew over 100% in Q1 of 2020 compared to last year. We have great people. We have a unique product with unprecedented clinical results and we are addressing a potentially used market need. Although we don’t yet have all the answers, if we don’t lose sight of our objectives, we will find ways to succeed. With that, we conclude our prepared remarks. We look forward to updating you on our future progress. Thank you for your interest and support.

Operator

[Operator Closing Remarks]

Disclaimer

This transcript is produced by AlphaStreet, Inc. While we strive to produce the best transcripts, it may contain misspellings and other inaccuracies. This transcript is provided as is without express or implied warranties of any kind. As with all our articles, AlphaStreet, Inc. does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company’s SEC filings. Neither the information nor any opinion expressed in this transcript constitutes a solicitation of the purchase or sale of securities or commodities. Any opinion expressed in the transcript does not necessarily reflect the views of AlphaStreet, Inc.

© COPYRIGHT 2020, AlphaStreet, Inc. All rights reserved. Any reproduction, redistribution or retransmission is expressly prohibited.

Most Popular

Infographic: How Cintas (CTAS) performed in Q1 2021

Cintas Corporation (NASDAQ: CTAS) reported first quarter 2021 earnings results today. Revenue was $1.75 billion, down 3.6% year-over-year.  Net income rose 19% to $300 million, or $2.78 per share, from

General Mills Q1 results top Wall Street expectations: Infographic

General Mills (NYSE: GIS) reported first-quarter 2020 financial results before the opening bell on Wednesday. The company reported a 9% increase in Q1 revenues to $4.36 billion, beating the Wall

JinkoSolar (JKS) Q2 Earnings: Key financials and quarterly highlights

JinkoSolar Holding Co., Ltd. (NYSE: JKS) reported second quarter 2020 earnings results today. Total revenues increased 22.2% year-over-year to RMB8.45 billion ($1.20 billion), exceeding the company’s guidance of $1.10 billion to $1.18 billion. The growth was

Top